April 1, 2021
Ono Pharmaceutical said on March 31 that it has submitted an application seeking to expand the label of its PD-1 inhibitor Opdivo (nivolumab) to add its use as an adjuvant therapy for resected urothelial cancer. The filing is based on...read more